During the first portion of the session, we will delve into the treatment and prevention strategies for both initial and recurrent C. difficile infections.

  

Learning objectives for the initial discussion:

• Gain insights into the most effective antimicrobial regimens for both initial and recurrent C. difficile infections.
• Explore the supplementary therapeutics employed to prevent the recurrence of C. difficile infections.
• Examine FDA-approved live biotherapeutic products and the supporting safety and efficacy data.

The latter half of the session will feature a product presentation focused on REBYOTA, the pioneering single-dose microbiota-based live biotherapeutic.

Learning objectives for the REBYOTA presentation:

• Comprehend the microbial composition, potency, and standardized manufacturing process behind REBYOTA.
• Evaluate the efficacy and safety data associated with REBYOTA.
• Engage in a discussion regarding the utilization of REBYOTA in clinical practice and its impact on the patient experience.

Speakers:

Jessica Gold, RD, CDN, CNSC
Clinical Nutritionist
Center for Advanced Digestive Care
New York Presbyterian/Weill Cornell Medical Center

 

 

Paul Feuerstadt MD, AGAF
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Attending Gastroenterologist
PACT-Gastroenterology Center
Hamden, CT

 

Jessica R. Allegretti, MD, MPH
Director, Crohn's and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology, Hepatology and Endoscopy
Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

 

Sahil Khanna, MBBS, MS, AGAF
Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic

 

 

Product Theater Presenter:

Candace Cotto, RN
Medical Research Center
Connecticut, LLC

 

 

 

Pricing:

Member	Nonmember
Free	Free

Original release date: Nov. 2, 2023

Expiration date: Nov. 1, 2024